UPDATED: Pfizer, BioNTech seek emergency COVID-19 vaccine nod

Pfizer sign
Pfizer and BioNTech expect to produce up to 50 million doses of their two-shot vaccine in 2020 with up to 1.3 billion doses to follow in 2021, Pfizer said earlier this month. (Tracy Staton)

Pfizer and BioNTech are off to the races. With early phase 3 data pointing to 95% efficacy, the companies have now confirmed they are gunning for an emergency use authorization for their COVID-19 vaccine.

This move was highly expected after BioNTech CEO Uğur Şahin, M.D., told CNN as much on Wednesday. That could mean an emergency green light in time for the new year, Şahin said.

"Depending on how fast this [review] is really accomplished, we might get an authorization, or conditional approval already in 2020 which might help us start distribution of the first vaccine batches already in 2020," Şahin told CNN. That said, he added that he couldn’t say how long the process would take.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

RELATED: Pfizer passes COVID-19 vaccine safety milestone, reveals 95% efficacy ahead of EUA

An early peek at the phase 3 data last week showed the mRNA vaccine candidate, BNT162b2, was more than 90% effective at preventing COVID-19 infections. Those numbers came from 92 patients, with the partners needing to collect data from at least 164 and build up at least two months of safety data before heading to the FDA for an emergency nod.

Those data arrived Wednesday, showing an efficacy rate of 95%. Of the patients who received placebo, 162 developed COVID-19, compared to eight people who got the mRNA vaccine.

The duo expects to produce up to 50 million doses of the two-shot vaccine regimen in 2020, with up to 1.3 billion doses to follow in 2021, Pfizer said earlier this month. Of the 1.3 billion, several million will come in the first four to five months of 2021, Şahin told CNN.

“I am confident that if everything goes well, and we have a very organized vaccine supply, that we could have a normal summer and winter 2021,” Şahin said.

RELATED: Moderna's COVID-19 vaccine aces phase 3, with no severe cases

Pfizer and BioNTech are the first to seek emergency use authorization, edging out Moderna, which reported phase 3 data on Monday. Its vaccine was 94.5% effective, with 90 cases of COVID-19—including all 11 severe cases seen so far in the study—striking the placebo group, compared to just five cases in the group who received its vaccine, mRNA-1273.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.